Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 837,001 | 52,198 | 81,381 | -23,848 | -38,872 |
| Depreciation Amortization | 77,989 | 51,218 | 26,024 | 103,300 | 77,613 |
| Income taxes - deferred | -854,199 | -5,864 | 10,603 | -82,760 | -59,780 |
| Accounts receivable | -32,915 | -8,028 | -31,898 | -37,852 | -61,803 |
| Other Working Capital | -145,869 | -127,971 | -134,332 | -101,092 | -110,612 |
| Other Operating Activity | 216,742 | 50,990 | 33,028 | 190,514 | 184,373 |
| Operating Cash Flow | $98,749 | $12,543 | $-15,194 | $48,262 | $-9,081 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -24,718 | -151,573 | 54,597 | 108,188 | 107,181 |
| PPE Investments | -16,127 | 443 | -40,554 | -145,026 | -94,241 |
| Purchase Sale Intangibles | -14,369 | -10,786 | 63,696 | 6,620 | 6,677 |
| Other Investing Activity | -23,803 | -20,217 | 63,361 | 5,812 | 4,930 |
| Investing Cash Flow | $-64,648 | $-171,347 | $77,404 | $-31,026 | $17,870 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 585,752 | 585,782 | N/A | N/A | 0 |
| Debt Repayment | -6,080 | -2,047 | -943 | -5,087 | -2,025 |
| Common Stock Issued | 60,268 | 46,927 | 10,116 | 31,611 | 21,768 |
| Common Stock Repurchased | -50,000 | -50,000 | N/A | N/A | 0 |
| Other Financing Activity | -42,667 | -36,645 | -28,844 | -101,198 | -98,459 |
| Financing Cash Flow | $547,273 | $544,017 | $-19,671 | $-74,674 | $-78,716 |
| Exchange Rate Effect | -3,145 | -3,759 | -3,353 | 902 | -835 |
| Beginning Cash Position | 437,446 | 437,446 | 437,446 | 493,982 | 493,982 |
| End Cash Position | 1,015,675 | 818,900 | 476,632 | 437,446 | 423,220 |
| Net Cash Flow | $578,229 | $381,454 | $39,186 | $-56,536 | $-70,762 |
| Free Cash Flow | |||||
| Operating Cash Flow | 98,749 | 12,543 | -15,194 | 48,262 | -9,081 |
| Capital Expenditure | -83,286 | -66,716 | -40,554 | -145,026 | -94,241 |
| Free Cash Flow | 15,463 | -54,173 | -55,748 | -96,764 | -103,322 |